» Articles » PMID: 29170526

Driver Pattern Identification over the Gene Co-expression of Drug Response in Ovarian Cancer by Integrating High Throughput Genomics Data

Overview
Journal Sci Rep
Specialty Science
Date 2017 Nov 25
PMID 29170526
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple types of high throughput genomics data create a potential opportunity to identify driver patterns in ovarian cancer, which will acquire some novel and clinical biomarkers for appropriate diagnosis and treatment to cancer patients. To identify candidate driver genes and the corresponding driving patterns for resistant and sensitive tumors from the heterogeneous data, we combined gene co-expression modules with mutation modulators and proposed the method to identify driver patterns. Firstly, co-expression network analysis is applied to explore gene modules for gene expression profiles through weighted correlation network analysis (WGCNA). Secondly, mutation matrix is generated by integrating the CNV data and somatic mutation data, and a mutation network is constructed from the mutation matrix. Thirdly, candidate modulators are selected from significant genes by clustering vertexs of the mutation network. Finally, a regression tree model is utilized for module network learning, in which the obtained gene modules and candidate modulators are trained for the driving pattern identification and modulators regulatory exploration. Many identified candidate modulators are known to be involved in biological meaningful processes associated with ovarian cancer, such as CCL11, CCL16, CCL18, CCL23, CCL8, CCL5, APOB, BRCA1, SLC18A1, FGF22, GADD45B, GNA15, GNA11, and so on.

Citing Articles

GNA15 predicts poor outcomes as a novel biomarker related to M2 macrophage infiltration in ovarian cancer.

Liu Q, Sun Y, Zhang T, Lin W, Zhang J, Zhang H Front Immunol. 2025; 16:1512086.

PMID: 39991148 PMC: 11842242. DOI: 10.3389/fimmu.2025.1512086.


Decoding FGF/FGFR Signaling: Insights into Biological Functions and Disease Relevance.

Edirisinghe O, Ternier G, Alraawi Z, Kumar T Biomolecules. 2025; 14(12.

PMID: 39766329 PMC: 11726770. DOI: 10.3390/biom14121622.


Comprehensive in silico analysis of prognostic and immune infiltrates for FGFs in human ovarian cancer.

Wang Y, Zhang H, Zhan Y, Li Z, Li S, Guo S J Ovarian Res. 2024; 17(1):197.

PMID: 39385288 PMC: 11465590. DOI: 10.1186/s13048-024-01496-z.


Histaminergic System and Inflammation-Related Genes in Normal Large Intestine and Tissues: Transcriptional Profiles and Relations.

Janikowska G, Janikowski T, Plato M, Mazurek U, Orchel J, Opilka M Int J Mol Sci. 2023; 24(5).

PMID: 36902343 PMC: 10002554. DOI: 10.3390/ijms24054913.


CCL23 in Balancing the Act of Endoplasmic Reticulum Stress and Antitumor Immunity in Hepatocellular Carcinoma.

Karan D Front Oncol. 2021; 11:727583.

PMID: 34671553 PMC: 8522494. DOI: 10.3389/fonc.2021.727583.


References
1.
Urquidi V, Kim J, Chang M, Dai Y, Rosser C, Goodison S . CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One. 2012; 7(5):e37797. PMC: 3357344. DOI: 10.1371/journal.pone.0037797. View

2.
Adib T, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J . Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer. 2004; 90(3):686-92. PMC: 2409606. DOI: 10.1038/sj.bjc.6601603. View

3.
Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L . CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 2015; 55(11):1688-1699. PMC: 5057350. DOI: 10.1002/mc.22419. View

4.
Yan Z, Liu Y, Wei Y, Zhao N, Zhang Q, Wu C . The functional consequences and prognostic value of dosage sensitivity in ovarian cancer. Mol Biosyst. 2017; 13(2):380-391. DOI: 10.1039/c6mb00625f. View

5.
Kumar R, Swamidass S, Bose R . Unsupervised detection of cancer driver mutations with parsimony-guided learning. Nat Genet. 2016; 48(10):1288-94. PMC: 5328615. DOI: 10.1038/ng.3658. View